Table 4:

Optimized Thresholds and Performance of Absolute SCr rise, Percent SCr rise and Max SCr to predict mortality using thresholds designed to optimize AUC.

Absolute SCr Rise
	Threshold	nAKI Incidence	Mortality	Sensitivity	Specificity	NPV	PPV	LR+	LR−	AUC	p-value*
≤29 weeks	≥ 0.3 mg/dl	95/170 (55.9%)	22 (23.2%)	0.92	0.5	0.97	0.23	1.8	0.16	0.71	ref
29–36 weeks	≥ 0.1 mg/dl	184/467 (39.4%)	11 (6.0%)	0.85	0.62	0.99	0.06	2.2	0.24	0.73	ref
≥36 weeks	≥ 0.1 mg/dl	126/353 (35.7%)	8 (6.3%)	0.67	0.65	0.98	0.06	1.9	0.51	0.66	ref
Percent SCr Rise
	Threshold	nAKI Incidence	Mortality	Sensitivity	Specificity	NPV	PPV	LR+	LR−	AUC	p-value*
≤29 weeks	≥ 37%	100/170 (58.8%)	21 (21.0%)	0.87	0.46	0.96	0.21	1.9	0.28	0.67	0.08
29–36 weeks	≥ 14%	170/467 (36.4%)	11 (6.5%)	0.85	0.65	0.99	0.06	2.4	0.23	0.75	0.002
≥36 weeks	≥ 8%	157/353 (44.5%)	9 (5.7%)	0.75	0.57	0.98	0.06	1.7	0.44	0.66	0.96
Absolute and/ or Percent SCr Rise
	Cutoff	nAKI Incidence	Mortality	Sensitivity	Specificity	NPV	PPV	LR+	LR−	AUC	p-value*
≤29 weeks	≥ 0.3/ 37%	103/ 170 (60.6%)	22 (21.4%)	0.92	0.44	0.97	0.21	1.6	0.18	0.68	0.004
29–36 weeks	≥ 0.1/14%	187/467 (40.0%)	11 (5.9%)	0.85	0.61	0.99	0.06	2.2	0.25	0.73	0.08
≥36 weeks	≥ 0.1/8%	158/353 (44.8%)	9 (5.7%)	0.75	0.56	0.98	0.06	1.7	0.45	0.66	0.93
Max SCR
	Threshold	nAKI Incidence	Mortality	Sensitivity	Specificity	NPV	PPV	LR+	LR−	AUC	p-value*
≤29 weeks	≥ 1.13 mg/dl	67/170 (39.4%)	15 (22.4%)	0.63	0.64	0.91	0.22	1.7	0.58	0.63	0.15
29–36 weeks	≥ 0.98 mg/dl	123/467 (26.3%)	10 (8.1%)	0.77	0.75	0.99	0.08	3.1	0.31	0.76	0.69
≥36 weeks	≥ 0.91 mg/dl	126/353 (35.7%)	7 (5.6%)	0.58	0.65	0.98	0.06	1.6	0.65	0.62	0.57

^*p-value for AUC - reference is absolute SCr change